OCLS: IPO Analysis, Six Month Review
re Oculus Innovative Sciences
Posted by PharmaTracker on Aug 13th, 2007 with stocks: OCLS
Note: Some information in this piece was taken from a report on Oculus published by Urchin Capital.
smallcap.seekingalpha.com
Includes tidbits in the section:
..."Before diving further into the product and the data supporting Microcyn/Dermacyn to figure out if it could possibly be sold for $70-$100 per bottle, there are many details in the S-1 that suggest something amiss with this company."...
Later in the blog entry PharmaTracker writes:
..."look into the “technology” behind Microcyn. So what is this stuff, anyhow?"...
Included in the blog is a table :
..."summarizes the concentrations of these components in a variety of common liquids, not to mention in products nearly identical to Microcyn, many of which are also on the market already:"...
Hypochlorous acid can be synthesized by one of the 3 methods:
...hydrolysis of chlorine gas (eq 1), electrolysis of salt solution (eqs 2a and 2b), and acidification of hypochlorite (eq 3)....
blog includes
...Novabay uses the third method, which basically amounts to adding bleach to saline solution and then lowering the pH with hydrochloric acid, whereas Oculus and Puricore use the second method (electrolysis)....
ends with:
...It is noteworthy that the Oculus clinical trials to date appear to adhere to almost none of the regulatory standards articulated by the FDA in its guidance document. Again, this is not really a surprise given that the company has admitted as much in its S-1. It does emphasize, however, that there are meaningful risks associated with Oculus undertaking a registration-quality phase III clinical trial of their topical antiseptic solution.... |
